Metabolomics, The Iceberg of Complexity and Clinical Utility


The genomic revolution continues to deliver research and clinical breakthroughs (CRISPR/Cas, WGS) that suggest greater precision and prediction is just ahead. And despite extraordinary complexities proteomics performance/cost has evolved into a $10- 20B annual market, spanning research to clinical applications on common new MS-based platforms, certainly one key for the validation and standardization essential to enable biomarkers robust enough for prime time diagnostics.

View PDF